Navigation Links
Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results
Date:1/28/2009

ensation from fiscal 2008 equity grants and a mark-to-market adjustment on Stock Appreciation Rights.

During the six-month period, the Company generated cash from operations of $13.6 million and reported $71.3 million of cash and interest bearing investment balances and total debt of $33.5 million at December 31, 2008.

The following chart presents a summary reconciliation of the Company's earnings per share for the six months ended December 31, 2008, and the Company's adjusted earnings per share for the comparable period of the prior fiscal year. See attached schedules for a detailed reconciliation between the non-GAAP and reported GAAP results.

                                                  Six Months         Year
                                              Ended December 31,  over Year %
    ($millions, except per share data)        2008        2007      Change
    Data as Reported:
    Pre-tax Income, As Reported              $15.3        $3.4       345%
    Adjust for:
         Discontinuation of Embolic
          Protection                             -        $0.3        n/m
         Acceleration of Stock Awards            -        $3.0        n/m
    Pre-tax Income, As Adjusted              $15.3        $6.8       127%
    Earnings Per Share, As
     Reported/Adjusted                       $0.87       $0.36       142%
      Supplemental Information related to
       Equity Compensation Expense:
    Equity Compensation Expense (Six Months
     ended December 31, 2007 prior to
     acceleration)                            $0.3        $1.5      (78%)
    Equity Compensation Related to
     Acceleration of Stock Awards                -        $3.0        n/m
    Total Equity Compensation Expense         $0.3        $4.4      (93%)
    Equity Compensation Expense Per Share
     (net of tax)                            $0.02       $0.23      (91%)

Supplemen
'/>"/>

SOURCE Kensey Nash Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related biology technology :

1. Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results
2. Kensey Nash Corporation Announces Its Third Quarter 2008 Earnings Release Date and Teleconference
3. Kensey Nash Receives FDA 510(k) Clearance for New Safe-Cross(R) Vessel Wall Detection Technology
4. Kensey Nash to Present at the Canaccord Adams Small-Cap Orthopedics Conference
5. Kensey Nash to Participate in the Sidoti Fifth Annual Palm Beach Emerging Growth Institutional Investor Forum Conference
6. Kensey Nash to Participate in the RBC Capital Markets Healthcare Conference
7. Kensey Nash to Present at the Sidoti Sixth Annual West Coast Emerging Growth Institutional Investor Forum Conference
8. Aerolase Reports Strong Sales in 2008 for Portable Aesthetic Lasers
9. GEN Reports on Growing Reliance on Microfluidics Technology
10. Novozymes Reports Strong 2008 Results
11. International Robotic Urology Symposium Reports on Benefits of Cooling During Robotic-Assisted Prostate Surgery and Introduces InnerCools New Investigational UroCool System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Aug. 28, 2015 /PRNewswire/ - RepliCel Life Sciences ... medicine company focused on the development of autologous ... quarter ended June 30, 2015, corporate highlights, and ... report are available at www.sedar.com ,  ... "RepliCel expects to launch its RCS-01 ...
(Date:8/28/2015)... ... August 28, 2015 , ... Since the initial launch of FireflySci Inc. (FFS) in early ... excellent customer service. Images such as the Fonz in a lab coat and Large ... to the humdrum spectroscopy field. , FireflySci is proud to be the only ...
(Date:8/27/2015)... ... August 27, 2015 , ... Capital Edge Consulting , ... problems, is pleased to announce their ranking as one of the top 5000 companies ... fastest-growing private companies across the nation. , “It is truly an honor to be ...
(Date:8/27/2015)... - Portage Biotech Inc. ("Portage") (OTC Market: PTGEF, ... Company Limited (Biohaven), announced today that dosing has ... a glutamate modulating agent. Biohaven filed an investigational ... clearance from the U.S. Food and Drug Administration ... 54% equity interest in Biohaven, a private company. ...
Breaking Biology Technology:RepliCel Reports Second Quarter 2015 Financial Results 2RepliCel Reports Second Quarter 2015 Financial Results 3RepliCel Reports Second Quarter 2015 Financial Results 4RepliCel Reports Second Quarter 2015 Financial Results 5Cuvette Manufacturer FireflySci Launches Back to School Deals with Complimentary Shipping On All Orders 2Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 2Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4
... will provide human safety and, pharmacodynamic ... to announce that its novel Innate Defense Regulator (IDR) ... time on April 27, 2009. The healthy volunteers were ... being performed for Inimex in Montreal with the approval ...
... confirms durable pain palliation as an acceptable primary endpoint, ... of market approval,BOTHELL, WA, April 28 /PRNewswire-FirstCall/ - OncoGenex ... that the company has reached an agreement with the ... of a second Phase 3 registration trial of OGX-011, ...
... SciLIMS Samples and Storage Management Product Line , ... ... , the premier provider of laboratory supplies and instrumentation to academic, ... new set of storage and sample management solutions. E&K is ...
Cached Biology Technology:Inimex Pharmaceuticals begins First Clinical Study of an Innate Defense Regulator 2OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer 2OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer 3OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer 4OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer 5OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer 6E&K Scientific Announces Partnership with Sciformatix 2
(Date:8/18/2015)... , Aug. 17, 2015 Research and ... of the "Global Biometric Authentication & Identification ... Estimation & Forecast, 2015-2020" report to their ... and identification systems market is expected to grow ... to 2020 and generate over $25 billion (approximately) ...
(Date:8/12/2015)... Aug. 12, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced that four of its fingerprint ... have officially been named FIDO Certified™ by the ... the certification, Synaptics, Natural ID™ fingerprint solutions are ... Framework (UAF) standard and are interoperable among other ...
(Date:8/6/2015)... and TELTOW, Germany , August ... Siggraph Conference, SensoMotoric Instruments (SMI) shows the ... , based on Epson,s Moverio BT-200 see-through ... platform. With this new solution, unprecedented quality and efficiency ... interaction with context-sensitive displays. For the first time, professionals ...
Breaking Biology News(10 mins):Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3
... comparing breastfed and formula fed infants across time showed ... than the potential risks associated with infant exposure to ... breastmilk, according to a report published in the December ... , a peer-reviewed journal published by Mary Ann Liebert, ...
... Clemson University professor of physics and astronomy Apparao Rao ... Society. Fellows are elected by their peers for outstanding ... than one half of 1 percent of the membership. ... carbon nanotubes and for elucidating the properties of carbon ...
... Unparalleled warming over the last few decades has triggered ... Western European lakes, say researchers at Queen,s University and ... reports that striking changes are now occurring in many ... rapidly warming Arctic, although typically many decades later. The ...
Cached Biology News:Benefits of breastfeeding outweigh risk of infant exposure to environmental chemicals in breastmilk 2Study links ecosystem changes in temperate lakes to climate warming 2
... peptidomimetics built on the flexible and ... These microarrays are available as part ... Service. Custom Probe Content ... specified. Thousands of customer specified peptide ...
... OPA1-01009, OPEP-01009 is a 16 amino acid (amino acids 3-18) ... (DFF). The sequence of this peptide is (amino to ... S - V - K - L - R - ... R - K(18). This peptide may be used ...
... standard microarray image analysis software because of ... tools, visualizations, automation capabilities, performance and ease ... every GenePix scanner, and it also imports ... types of arrays. A wide range of ...
... Applications Package Superior Protein Detection and ... ProXPRESS 2D Proteomic Imaging System is a ... and general life science research applications. ProXPRESS ... of all dyes in the UV and ...
Biology Products: